Antiva Biosciences Funding: $100M Raised, Series E (2023)
Antiva Biosciences is based in South San Francisco, CA. It has raised $100M in total funding. Latest round: Series E. Backed by MPM BioImpact Capital.
Antiva Biosciences funding overview
Antiva Biosciences is based in South San Francisco, CA. Antiva Biosciences has raised $100M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series E announced in April 2023. The round record for Antiva Biosciences runs through 2023; nothing later has been disclosed. Investors on record include MPM BioImpact Capital.
Antiva Biosciences at a glance
Total raised
$100M
Latest round
Series E
Latest round date
April 2023
Headquarters
South San Francisco, CA
Notable investors
MPM BioImpact Capital
Frequently asked about Antiva Biosciences funding
How much has Antiva Biosciences raised?
Antiva Biosciences has raised $100M in total disclosed funding across the rounds on record.
Who has invested in Antiva Biosciences?
MPM BioImpact Capital are named among the investors backing Antiva Biosciences.
What was the latest Antiva Biosciences funding round?
The most recent disclosed round is a Series E, announced in April 2023.
Where is Antiva Biosciences based?
Antiva Biosciences is based in South San Francisco, CA.
When did Antiva Biosciences last raise?
The last disclosed Antiva Biosciences round closed in April 2023 at Series E.
Antiva Biosciences totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in South San Francisco below to benchmark round size and investor mix.
